Polymarket (Global)
Skin cancer vaccine FDA approved by June 30, 2027?
June 30, 2027
Updated 40m ago · Settles Jul 1, 27
Polymarket (Global) YES
16¢
Bid 15¢ · Ask 16¢
Pricedger fair probability
13%
Deterministic model estimate
Potential edge
+1.6 pts
On NO after fees · low confidence
Volume
51,326
Fine-print risk
58/100
Resolution-rule audit
Resolution rules — summary
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by June 30, 2027, 11:59 PM ET. Otherwise, this market will resolve to "No". Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, togethe…
Full clause-by-clause forensic audit is available inside the terminal.
Whale flow & Smart Money Divergence
See whether large traders are positioning with or against the price move on this contract.
Model ensemble & AI Deep Dive
Quant, base-rate and AI estimates compared on one scale, with clause-level fine-print analysis.
Quarter-Kelly paper sizing
Exact stake, expected value and scenario matrix for your bankroll — paper trading only.
Locked previews show illustrative sample figures.
The full Pricedger analysis is inside the terminal
Visible Ensemble consensus, AI Deep Dive with clause-by-clause fine print, whale flow and Smart Money Divergence, cross-exchange gaps, price history and quarter-Kelly paper sizing. 7-day free trial, no card required.
See the full Pricedger analysisResearch and paper trading only — not financial advice. Model estimates can be wrong. Not affiliated with Kalshi or Polymarket. Methodology